

Table S1. Crystal data and structure refinement for **2**, **3**, and **4·2CH₃CN**.

Compound	2	3	4·2CH₃CN
Empirical formula	C ₃₄ H ₅₁ B ₁₂ CdN ₇ O ₃	C ₂₄ H ₃₂ N ₆ O ₄ Zn	C ₂₄ H ₄₆ B ₁₂ N ₈
Formula weight	847.93	533.92	576.41
Temperature/K	100.00	100.00	100.00
Crystal system	triclinic	monoclinic	triclinic
Space group	<i>P</i> -1	<i>P</i> 2 ₁ / <i>n</i>	<i>P</i> -1
<i>a</i> /Å	10.494(2)	13.8012(15)	8.036(2)
<i>b</i> /Å	12.322(4)	12.687(2)	10.416(4)
<i>c</i> /Å	18.644(6)	15.896(2)	10.700(4)
α /°	79.582(13)	90	106.211(14)
β /°	87.114(11)	115.116(5)	91.220(12)
γ /°	75.755(11)	90	109.216(10)
Volume/Å ³	2298.1(12)	2520.3(7)	805.8(4)
<i>Z</i>	2	4	1
$\rho_{\text{calc}}/\text{cm}^3$	1.225	1.407	1.188
μ/mm^{-1}	0.515	1.016	0.067
<i>F</i> (000)	872.0	1120.0	306.0
Radiation	MoK α (λ = 0.71073)	MoK α (λ = 0.71073)	MoK α (λ = 0.71073)
Index ranges	-13 ≤ <i>h</i> ≤ 13, -16 ≤ <i>k</i> ≤ 12, -24 ≤ <i>l</i> ≤ 18	-19 ≤ <i>h</i> ≤ 19, -17 ≤ <i>k</i> ≤ 13, -22 ≤ <i>l</i> ≤ 22	-11 ≤ <i>h</i> ≤ 11, -10 ≤ <i>k</i> ≤ 14, -15 ≤ <i>l</i> ≤ 14
Reflections collected	14162	20891	6246
Independent reflections	10200 [<i>R</i> _{int} = 0.0263, <i>R</i> _{sigma} = 0.0803]	7064 [<i>R</i> _{int} = 0.0333, <i>R</i> _{sigma} = 0.0422]	4553 [<i>R</i> _{int} = 0.0221, <i>R</i> _{sigma} = 0.0549]
Data/restraints/parameters	10200/0/520	7064/0/339	4553/0/201
Goodness-of-fit on <i>F</i> ²	1.021	1.028	1.037
Final <i>R</i> indexes [<i>I</i> ≥ 2σ (<i>I</i>)]	<i>R</i> ₁ = 0.0503, w <i>R</i> ₂ = 0.1050	<i>R</i> ₁ = 0.0336, w <i>R</i> ₂ = 0.0728	<i>R</i> ₁ = 0.0483, w <i>R</i> ₂ = 0.1084
Final <i>R</i> indexes [all data]	<i>R</i> ₁ = 0.0727, w <i>R</i> ₂ = 0.1149	<i>R</i> ₁ = 0.0506, w <i>R</i> ₂ = 0.0784	<i>R</i> ₁ = 0.0656, w <i>R</i> ₂ = 0.1171




Figure S1. IR spectra of ligand L^1 (blue) and complex **1** (red).




Figure S2. IR spectra of ligand L^2 (blue) and complex **2** (red).




Figure S3. IR spectra of ligand L^3 (blue) and complex 3 (red).




Figure S4. IR spectra of ligand L^3 (blue) and a precipitate containing $(HBz-NH_2)_2[B_{12}H_{12}]$ (**4**) and a cadmium(II) complex with salicylaldehyde (red).




Figure S5. UV-vis absorption spectra of ligand L^1 (blue) and complex **1** (red).




Figure S6. UV-vis absorption spectra of ligand L^2 (blue) and complex **2** (red).




Figure S7. UV-vis absorption spectra of ligand L^3 (blue) and complex **3** (red).




Figure S8. ^1H NMR spectrum of *N*-(4-methoxyphenyl)-1-(1-methylbenzimidazol-2-yl)methanimine (L^1).




Figure S9. ¹H NMR spectrum of 4-methoxy-*N*-[(1-methylbenzimidazol-2-yl)methyl]aniline (L²).




Figure S10. ^1H NMR spectrum of 2-[(*E*)-(1-propylbenzimidazol-2-yl)iminomethyl]phenol (L^3).




Figure S11. ^{13}C NMR spectrum of *N*-(4-methoxyphenyl)-1-(1-methylbenzimidazol-2-yl)methanimine (L^1).




Figure S12. ¹³C NMR spectrum of 4-methoxy-*N*-[(1-methylbenzimidazol-2-yl)methyl]aniline (L²).




Figure S13. ^{13}C NMR spectrum of 2-[(*E*)-(1-propylbenzimidazol-2-yl)iminomethyl]phenol (L^3).




Figure S14. Structure of ligand L².